Amivantamab + Lazertinib

Type: drug

Status: FDA Approved

Developer: Janssen/J&J

Breakthrough Summary

No summary available.

Mechanism of Action

Bispecific antibody + TKI combo for EGFR-mutant NSCLC

Year: 2024